Literature DB >> 11748066

Decreased expression of myocardial eNOS and caveolin in dogs with hypertrophic cardiomyopathy.

A Piech1, P E Massart, C Dessy, O Feron, X Havaux, N Morel, J-L Vanoverschelde, J Donckier, J-L Balligand.   

Abstract

Because nitric oxide (NO) regulates cardiac and vessel contraction, we compared the expression and activity of the endothelial NO synthase (eNOS) and caveolin, which tonically inhibits eNOS in normal and hypertrophic cardiomyopathic hearts. NOS activity (L-[(3)H]citrulline formation), eNOS immunostaining, and caveolin abundance were measured in heart tissue of 23 mongrel dogs before and at 3 and 7 wk of perinephritic hypertension (PHT). Hemodynamic parameters in vivo and endothelial NO-dependent relaxation of macro- and coronary microvessels in vitro were assessed in the same animals. eNOS immunostaining and total calcium-dependent NOS activity decreased at 7 wk in all four heart cavities (in left ventricle, from 17.0 +/- 1.3 to 0.2 +/- 0.2 fmol. min(-1). mg protein(-1), P < 0.001). Caveolin-1 and -3 also decreased in PHT dog hearts. Accordingly, basal vascular tone was preserved, but maximal endothelial NO-dependent relaxation was impaired in all vessels from 7-wk PHT dogs. The latter had preserved systolic function but impaired diastolic relaxation [relaxation time constant (T(1)), 25.1 +/- 0.9 vs. 22.0 +/- 1 ms in controls; P < 0.05]. Peripheral infusion of the NOS inhibitor N(G)-nitro-L-arginine methyl ester increased mean aortic pressure in both groups and reduced diastolic (T(1), 31.9 +/- 1.4 ms) and systolic function in PHT dogs (DP40, 47.5 +/- 2.5 vs. 59.4 +/- 3.8 s(-1) in control animals). In conclusion, both eNOS and caveolin proteins are decreased in the hypertrophic hearts of PHT dogs. This is associated with altered maximal (but not basal) vascular relaxation and impaired diastolic function. Further degradation of cardiac function after NOS inhibition suggests a critical role of residual NOS activity, probably supported by the concurrent downregulation of caveolin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748066     DOI: 10.1152/ajpheart.2002.282.1.H219

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  17 in total

Review 1.  Sarcolemmal dependence of cardiac protection and stress-resistance: roles in aged or diseased hearts.

Authors:  Louise E See Hoe; Lauren T May; John P Headrick; Jason N Peart
Journal:  Br J Pharmacol       Date:  2016-09-09       Impact factor: 8.739

2.  Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats.

Authors:  Annayya R Aroor; James R Sowers; Shawn B Bender; Ravi Nistala; Mona Garro; Irina Mugerfeld; Melvin R Hayden; Megan S Johnson; Muhammad Salam; Adam Whaley-Connell; Vincent G Demarco
Journal:  Endocrinology       Date:  2013-05-07       Impact factor: 4.736

Review 3.  Gasotransmitters in pregnancy: from conception to uterine involution.

Authors:  Damian D Guerra; K Joseph Hurt
Journal:  Biol Reprod       Date:  2019-07-01       Impact factor: 4.285

4.  17 beta-estradiol attenuates pressure overload-induced myocardial hypertrophy through regulating caveolin-3 protein in ovariectomized female rats.

Authors:  Yu-Hong Cui; Zhi Tan; Xiao-Dong Fu; Qiu-Ling Xiang; Jin-Wen Xu; Ting-Huai Wang
Journal:  Mol Biol Rep       Date:  2010-12-18       Impact factor: 2.316

Review 5.  Caveolin: a key target for modulating nitric oxide availability in health and disease.

Authors:  Bikramjit Dhillon; Mitesh V Badiwala; Shu-Hong Li; Ren-Ke Li; Richard D Weisel; Donald A G Mickle; Paul W M Fedak; Vivek Rao; Subodh Verma
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

Review 6.  Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart.

Authors:  Soban Umar; Arnoud van der Laarse
Journal:  Mol Cell Biochem       Date:  2009-07-19       Impact factor: 3.396

7.  Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype.

Authors:  David S Park; Scott E Woodman; William Schubert; Alex W Cohen; Philippe G Frank; Madhulika Chandra; Jamshid Shirani; Babak Razani; Baiyu Tang; Linda A Jelicks; Stephen M Factor; Louis M Weiss; Herbert B Tanowitz; Michael P Lisanti
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 8.  Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice.

Authors:  P B Massion; J-L Balligand
Journal:  J Physiol       Date:  2003-01-01       Impact factor: 5.182

Review 9.  Nitric oxide and coronary vascular endothelium adaptations in hypertension.

Authors:  Andrew S Levy; Justin C S Chung; Jeffrey T Kroetsch; James W E Rush
Journal:  Vasc Health Risk Manag       Date:  2009-12-29

Review 10.  Nitric oxide synthases in heart failure.

Authors:  Ricardo Carnicer; Mark J Crabtree; Vidhya Sivakumaran; Barbara Casadei; David A Kass
Journal:  Antioxid Redox Signal       Date:  2012-09-20       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.